Histological healing in inflammatory bowel disease: A still unfulfilled promise

World Journal of Gastroenterology

Volumn 19, Issue 7, 2013, Pages 968-978

  Villanacci, Vincenzo ^a   Antonelli, Elisabetta ^b   Geboes, Karel ^c   Casella, Giovanni ^d   Bassotti, Gabrio ^b  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Desio General Hospital   (Italy)

Author keywords

Crohn's disease; Healing; Histology; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; HEPARIN; HYDROCORTISONE SODIUM SUCCINATE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG DOSAGE FORM COMPARISON; EDITORIAL; ENTERITIS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ULCERATIVE COLITIS;

EID: 84874379714     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i7.968     Document Type: Editorial

References (90)

1. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 2011; 63: 629-642 [PMID: 21857074]
2. Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 2011; 8: 646-656 [PMID: 21970871 DOI: 10.1038/nrgastro.2011.172]
3. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260; quiz 1520 [PMID: 19596014 DOI: 10.1053/j.gastro.2009.06.061]
4. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786 [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038]
5. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-1385 [PMID: 15233681 DOI: 10.1111/ j.1572-0241.2004.40036.x]
6. Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 Suppl 3: 337-342 [PMID: 11953331 DOI: 10.1136/gut.50.suppl_3. iii37]
7. Bardella MT, Velio P, Cesana BM, Prampolini L, Casella G, Di Bella C, Lanzini A, Gambarotti M, Bassotti G, Villanacci V. Coeliac disease: a histological follow-up study. Histopathology 2007; 50: 465-471 [PMID: 17448022 DOI: 10.1111/ j.1365-2559.2007.02621.x]
8. Cornaggia M, Leutner M, Mescoli C, Sturniolo GC, Gullotta R. Chronic idiopathic inflammatory bowel diseases: the histology report. Dig Liver Dis 2011; 43 Suppl 4: S293-S303 [PMID: 21459335 DOI: 10.1016/S1590-8658(11)60585-9]
9. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29 [PMID: 19949430 DOI: 10.1038/nrgastro.2009.203]
10. Vatn MH. Mucosal healing: impact on the natural course or therapeutic strategies. Dig Dis 2009; 27: 470-475 [PMID: 19897962 DOI: 10.1159/000233285]
11. Villanacci V, Manenti S, Antonelli E, Chiudinelli M, Giuliano V, Bassotti G. Non-IBD colitides: clinically useful histopathological clues. Rev Esp Enferm Dig 2011; 103: 366-372 [PMID: 21770683 DOI: 10.4321/S1130-01082011000700006]
12. Jenkins D, Balsitis M, Gallivan S, Dixon MF, Gilmour HM, Shepherd NA, Theodossi A, Williams GT. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93-105 [PMID: 9155688 DOI: 10.1136/jcp.50.2.93]
13. Schumacher G, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol 1994; 29: 318-332 [PMID: 8047806 DOI: 10.3109/00365529409094843]
14. Theodossi A, Spiegelhalter DJ, Jass J, Firth J, Dixon M, Leader M, Levison DA, Lindley R, Filipe I, Price A. Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut 1994; 35: 961-968 [PMID: 8063225 DOI: 10.1136/gut.35.7.961]
15. Rubio CA, Johansson C, Kock Y. A quantitative method of estimating inflammation in the rectal mucosa. III. Chronic ulcerative colitis. Scand J Gastroenterol 1982; 17: 1083-1087 [PMID: 7167739]
16. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984; 86: 104-113 [PMID: 6689653]
17. Seldenrijk CA, Morson BC, Meuwissen SG, Schipper NW, Lindeman J, Meijer CJ. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991; 32: 1514-1520 [PMID: 1773958 DOI: 10.1136/gut.32.12.1514]
18. Rubio CA, Johansson C, Uribe A, Kock Y. A quantitative method of estimating inflammation in the rectal mucosa. IV. Ulcerative colitis in remission. Scand J Gastroenterol 1984; 19: 525-530 [PMID: 6463576]
19. Jenkins D, Goodall A, Drew K, Scott BB. What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. J Clin Pathol 1988; 41: 72-79 [PMID: 3343381 DOI: 10.1136/jcp.41.1.72]
20. Scott BB, Goodall A, Stephenson P, Jenkins D. Rectal mucosal plasma cells in inflammatory bowel disease. Gut 1983; 24: 519-524 [PMID: 6852632 DOI: 10.1136/gut.24.6.519]
21. Rubio CA, Orrego A, Nesi G, Finkel Y. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol 2007; 60: 1268-1272 [PMID: 17293387 DOI: 10.1136/ jcp.2006.045336]
22. Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn's disease. Tech Coloproctol 2009; 13: 295-300 [PMID: 19774438 DOI: 10.1007/s10151-009-0538-7]
23. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-1318 [PMID: 13316140 DOI: 10.1136/bmj.1.4979.1315]
24. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-537 [PMID: 6979471 DOI: 10.1007/BF01296733]
25. Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-95 [PMID: 3949241 DOI: 10.1136/ gut.27.1.92]
26. Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-462 [PMID: 3602926 DOI: 10.3109 /00365528708991491]
27. Danielsson A, Hellers G, Lyrenäs E, Löfberg R, Nilsson A, Olsson O, Olsson SA, Persson T, Salde L, Naesdal J. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987-992 [PMID: 3317784 DOI: 10.3109 /00365528708991947]
28. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-1389 [PMID: 2896139]
29. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-178 [PMID: 1864537 DOI: 10.1136/gut.32.2.174]
30. Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-875 [PMID: 8352372 DOI: 10.1097/ 00000478-199309000-00002]
31. Beattie RM, Schiffrin EJ, Donnet-Hughes A, Huggett AC, Domizio P, MacDonald TT, Walker-Smith JA. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994; 8: 609-615 [PMID: 7696450 DOI: 10.1111/j.1365-2036.1994.tb00338.x]
32. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-553 [PMID: 8823568 DOI: 10.1097/00042737-199606000-00010]
33. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-409 [PMID: 10940279 DOI: 10.1136/gut.47.3.404]
34. D'Argenio G, Cosenza V, Riegler G, Della Valle N, Deritis F, Mazzacca G. Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis. Dig Dis Sci 2001; 46: 649-657 [PMID: 11318547]
35. Nicholls S, Domizio P, Williams CB, Dawnay A, Braegger CP, MacDonald TT, Walker-Smith JA. Cyclosporin as initial treatment for Crohn's disease. Arch Dis Child 1994; 71: 243-247 [PMID: 7979499 DOI: 10.1136/adc.71.3.243]
36. Breese EJ, Michie CA, Nicholls SW, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn's disease. Aliment Pharmacol Ther 1995; 9: 547-552 [PMID: 8580276 DOI: 10.1111/j.1365-2036.1995. tb00419.x]
37. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267 [PMID: 9453485 DOI: 10.1016/S0016-5085(98)70476-7]
38. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Schölmerich J, Reinisch W. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 Suppl 1: 11-15 [PMID: 16481628 DOI: 10.1136/gut.2005.081950a]
39. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW, Kupcinskas L, Lakatos PL, Mantzaris GJ, Schreiber S, Villanacci V, Warren BF. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23 [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001]
40. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, Danese S, Sturm A. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-483 [PMID: 21939925 DOI: 10.1016/ j.crohns.2011.06.009]
41. Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL, Panés J, Rimola J, Louis E. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011; 5: 484-498 [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003]
42. Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, Nakagawa K, Kayazawa M, Hirata I, Katsu K. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3513-3520 [PMID: 10606313 DOI: 10.1111/j.1572-0241. 1999.01640.x]
43. Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol 2003; 36: 120-125 [PMID: 12544193 DOI: 10.1097/00004836-200302000-00006]
44. Kleer CG, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 1998; 22: 983-989 [PMID: 9706978 DOI: 10.1097/00000478-199808000-00008]
45. Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006; 12: 979-994 [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e]
46. TRUELOVE SC, HAMBLING MH. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J 1958; 2: 1072-1077 [PMID: 13584853 DOI: 10.1136/bmj.2.5104.1072]
47. Sommers SC, Korelitz BI. Mucosal-cell counts in ulcerative and granulomatous colitis. Am J Clin Pathol 1975; 63: 359-365 [PMID: 234674]
48. Ruddell WS, Dickinson RJ, Dixon MF, Axon AT. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885-889 [PMID: 7002739 DOI: 10.1136/gut.21.10.885]
49. Lee FI, Jewell DP, Mani V, Keighley MR, Kingston RD, Record CO, Grace RH, Daniels S, Patterson J, Smith K. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996; 38: 229-233 [PMID: 8801202 DOI: 10.1136/gut.38.2.229]
50. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998; 115: 525-532 [PMID: 9721148 DOI: 10.1016/S0016-5085(98)70131-3]
51. Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1015-1022 [PMID: 10930895 DOI: 10.1046/ j.1365-2036.2000.00802.x]
52. Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A, Castiglione GN, Varoli G, Campieri M. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002; 16: 1109-1116 [PMID: 12030952 DOI: 10.1046/ j.1365-2036.2002.01298.x]
53. Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovács A, Faszczyk M, Razbadauskas A, Margus B, Stolte M, Müller R, Greinwald R. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23: 303-312 [PMID: 16393311 DOI: 10.1111/j.1365-2036.2006.02743.x]
54. Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989; 30: 675-679 [PMID: 2567266 DOI: 10.1136/gut.30.5.675]
55. Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 61-68 [PMID: 11856079]
56. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 69-77 [PMID: 11856080 DOI: 10.1046/ j.1365-2036.2002.01151.x]
57. Malchow H, Gertz B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 415-423 [PMID: 11876694 DOI: 10.1046/ j.1365-2036.2002.01199.x]
58. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43 [PMID: 15017515 DOI: 10.1053/jcgh.2003.50006]
59. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 421-427 [PMID: 15867580 DOI: 10.1097/01.MIB.0000158386. 25660.1e]
60. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, doubledummy, randomised, non-inferiority trial. Gut 2009; 58: 233-240 [PMID: 18832520 DOI: 10.1136/gut.2008.154302]
61. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 1751-1759 [PMID: 12269968 DOI: 10.1046/j.1365-2036.2002.01340.x]
62. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329 [PMID: 11313301 DOI: 10.1053/gast.2001.23983]
63. Hanauer SB. The role of biologics in ulcerative colitis. Dig Dis 2010; 28: 497-500 [PMID: 20926878 DOI: 10.1159/000320408]
64. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201 [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054]
65. Hassan C, Ierardi E, Burattini O, De Francesco V, Zullo A, Stoppino G, Panella C, Morini S. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811-817 [PMID: 17652038 DOI: 10.1016/ j.dld.2007.06.003]
66. Fratila OC, Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J Gastrointestin Liver Dis 2010; 19: 147-153 [PMID: 20593047]
67. D'Ovidio V, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, Caprilli R. Mucosal features and granulocytemonocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 2006; 38: 389-394 [PMID: 16569521 DOI: 10.1016/j.dld.2005.12.005]
68. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-818 [PMID: 2179031 DOI: 10.1016/0016-5085(90)90002-I]
69. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn' s disease. Inflamm Bowel Dis 2009; 15: 375-382 [PMID: 19009634 DOI: 10.1002/ibd.20777]
70. Baars JE, Vogelaar L, Wolfhagen FH, Biermann K, Kuipers EJ, van der Woude CJ. A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial. J Crohns Colitis 2010; 4: 661-668 [PMID: 21122577 DOI: 10.1016/j.crohns.2010.07.011]
71. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-1481 [PMID: 9136824]
72. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671 [PMID: 10536324 DOI: 10.1016/S0016-5107(99)80017-0]
73. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356 [PMID: 2492786]
74. Laharie D, Reffet A, Belleannée G, Chabrun E, Subtil C, Razaire S, Capdepont M, de Lédinghen V. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011; 33: 714-721 [PMID: 21235604 DOI: 10.1111/j.1365-2036.2010.04569.x]
75. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034 [PMID: 10220494]
76. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-28 [PMID: 9869598 DOI: 10.1016/ S0016-5085(99)70224-6]
77. Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21: 1741-1754 [PMID: 16307694 DOI: 10.1185/030079905X65457]
78. D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001; 96: 2564-2568 [PMID: 11569676 DOI: 10.1111/j.1572-0241.2001.04705.x]
79. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005; 11: 580-588 [PMID: 15905706 DOI: 10.1097/01.MIB.0000161307.58327.96]
80. Saverymuttu SH, Camilleri M, Rees H, Lavender JP, Hodgson HJ, Chadwick VS. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986; 90: 1121-1128 [PMID: 3956932]
81. Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis 2007; 39: 438-444 [PMID: 17369114 DOI: 10.1016/j.dld.2007.01.008]
82. Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4: 285-291 [PMID: 20528116 DOI: 10.1586/egh.10.22]
83. van Assche G, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets 2010; 11: 227-233 [PMID: 20210770 DOI: 10.2174/138945010790309902]
84. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012; 18: 174-179 [PMID: 21674731 DOI: 10.1002/ibd.21792]
85. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn' s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther 2011; 34: 1-10 [PMID: 21539588 DOI: 10.1111/j.1365-2036.2011.04679.x]
86. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-1619 [PMID: 19700435 DOI: 10.1136/gut.2009.178665]
87. Arijs I, Quintens R, Van Lommel L, Van Steen K, De Hertogh G, Lemaire K, Schraenen A, Perrier C, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010; 16: 2090-2098 [PMID: 20848504 DOI: 10.1002/ibd.21301]
88. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20 [PMID: 11208709 DOI: 10.1053/ gast.2001.20912]
89. Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 2011; 17: 194-198 [PMID: 21546723 DOI: 10.4103/1319-3767.80383]
90. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105; quiz 1340-1341 [PMID: 17919486 DOI: 10.1053/ j.gastro.2007.08.001]